Skip to main content
. Author manuscript; available in PMC: 2016 Mar 15.
Published in final edited form as: J Community Support Oncol. 2015 Mar;13(3):113–116. doi: 10.12788/jcso.0117

TABLE 3.

Adverse events due to guideline nonadherence in high- and intermediate-risk chemotherapy initiations in which primary prophylaxis was indicated

Regimen risk No. of nonadherent regimens Neutropenic episode with dose delay, n (%) Neutropenic episode without dose delay, n (%) Febrile neutropenia with hospital admission, n (%)
High 5 0 (0) 0 (0) 2 (40)
Intermediate + at least 1 risk factor 59 7 (11.9) 5 (8.5) 3 (5.1)
    Total 64 7 (10.9) 5 (7.8) 5 (7.8)